



For Immediate Release

July 8, 2024

Christopher Sweeney Named Executive Director, Intellectual Property at Acuitas Therapeutics (USA), Inc.

Vancouver, B.C. – Acuitas Therapeutics, Inc.’s Chief Legal Officer & Vice President of Business Development, Miranda Lam, KC, recently announced that Christopher Sweeney had joined Acuitas Therapeutics (USA), Inc. as Executive Director of Intellectual Property (IP).

In this senior role, Mr. Sweeney oversees the IP program, focusing on aligning Acuitas’ global IP strategy with its business objectives and supporting its robust internal research and development (R&D) program. Acuitas Therapeutics (USA) is a subsidiary of the Vancouver-based company Acuitas Therapeutics, Inc.

“We are fortunate to have an IP leader like Chris join the team,” said Ms. Lam. “He brings an immense amount of experience working with large, multinational and growing biotech companies with diverse international IP portfolios. He has more than two decades of experience as a U.S. patent attorney – and his supportive, engaging and collaborative approach aligns with how we work at Acuitas. We are thrilled that he has joined the team.”

Mr. Sweeney has an exceptional background in organic chemistry, biochemistry and patent law. He holds a Bachelor of Science in Biochemistry (Gonzaga University), a Master of Science in Chemistry (University of Oregon), and a Juris Doctor with Intellectual Property Concentration (University of Washington). Prior to joining Acuitas, he was Executive Director of IP at Pfizer, Inc. (formerly SEAGEN, Inc.) and before that, he was an equity partner with IP law firm Knobbe Martens Olsen & Bear, LLP. Mr. Sweeney brings vital expertise in developing and executing IP strategies in collaboration with leaders in business development, strategic alliance management and R&D.

When not busy overseeing the growing Acuitas IP portfolio, Mr. Sweeney enjoys spending time with his husband, daughter and son, and their two dogs.

About Acuitas Therapeutics, Inc.

Vancouver-based Acuitas Therapeutics, Inc. (www.acuitastx.com) partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes, to advance nucleic acid therapeutics into clinical development and commercialization. Acuitas’ lipid nanoparticle (LNP) technology is clinically validated, enabling Alnylam Pharmaceuticals’ ONPATTRO® for the treatment of people with a rare genetic and



otherwise fatal disorder known as transthyretin amyloidosis and the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, which has protected billions of people in more than 180 countries. Acuitas has also helped to enable the first human proof-of-concept for genome base editing to treat a serious genetic disease. The company is currently focused on further innovations to its LNP carriers to advance the development of novel gene therapies, such as epigenetic medicines, to modulate gene expression without genetic editing to treat a range of diseases, including cancer. In addition, Acuitas works with partners on the development of improved vaccines – such as multi-valent vaccines to prevent a range of infectious diseases (including malaria, HIV/AIDS and tuberculosis) – and on novel therapeutic vaccines against cancer, including personalized cancer vaccines.

-END-